<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valacyclovir: An overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valacyclovir: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Valacyclovir: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a> is the valyl ester of the antiviral drug <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> [<a href="#rid1">1</a>]. Acting as an oral prodrug, valacyclovir is converted in vivo to acyclovir. Acyclovir, a nucleoside analog, is phosphorylated by virally-encoded thymidine kinase and subsequently by cellular enzymes, yielding acyclovir triphosphate, which competitively inhibits viral DNA polymerase. (See  <a class="medical medical_review" href="/d/html/8332.html" rel="external">"Acyclovir: An overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BASIC PHARMACOKINETICS</span><span class="headingEndMark"> — </span>The antiviral activity of <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> reflects its in vivo conversion to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, which is active against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at the oral doses approved by the US Food and Drug Administration [<a href="#rid2">2,3</a>]. </p><p><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a> has three to fivefold greater oral bioavailability (about 55 percent) than <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>; it then undergoes rapid and extensive first-pass intestinal and/or hepatic hydrolysis to yield acyclovir and L-valine [<a href="#rid2">2,3</a>]. Food does not affect absorption.</p><p><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a>, at a dose of 250 mg four times daily, generates essentially the same <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> AUC (area under the curve, or exposure over 24 hours) as oral acyclovir at a dose 800 mg five times daily [<a href="#rid3">3</a>]. Valacyclovir, at a dose of 1000 mg three times daily, produces a similar acyclovir AUC as intravenous acyclovir at a dose of 5 mg/kg every eight hours [<a href="#rid4">4</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> generates higher peak levels than oral <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>. Although this feature may confer more potent activity, it may also increase the risk of renal toxicity due to precipitation of acyclovir crystals in the renal tubules [<a href="#rid3">3</a>] (see  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury"</a>). In addition, the safety of valacyclovir at doses higher than those approved by the US Food and Drug Administration, especially in immunocompromised persons, remains controversial.</p><p>The main route of <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> elimination is renal, and dose modification is recommended for patients with a creatinine clearance below 30 mL/min/1.73 m2. Dose adjustment is not required in patients with hepatic impairment [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H499155513"><span class="h1">MECHANISM OF RESISTANCE</span><span class="headingEndMark"> — </span>The mechanisms of resistance to <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> are identical to those described for <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced or absent thymidine kinase</p><p class="bulletIndent1"><span class="glyph">●</span>Altered thymidine kinase activity resulting in decreased <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> phosphorylation</p><p class="bulletIndent1"><span class="glyph">●</span>Altered viral DNA polymerase with decreased affinity for <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> triphosphate</p><p></p><p>(See  <a class="medical medical_review" href="/d/html/8332.html" rel="external">"Acyclovir: An overview", section on 'Mechanism of resistance'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>When administered at approved doses (up to 1000 mg three times daily, or two 2000 mg doses separated by 12 hours), <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> has been remarkably well tolerated, similar to the experience with <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> [<a href="#rid1">1,3</a>]. (See  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8287.html" rel="external">"Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults"</a>.)</p><p>However, a trial examining the effectiveness of high-dose <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (2000 mg four times daily) in preventing cytomegalovirus (CMV) disease was halted when interim analysis revealed significantly shorter survival in patients receiving this regimen, with cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome being reported [<a href="#rid6">6</a>]. This complication has also been observed at this high dose in recipients of allogeneic bone marrow or kidney transplants [<a href="#rid1">1</a>].</p><p>Much of this phenomenon was attributed to the development of a thrombotic microangiopathy associated with <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>; however, causality has not been established conclusively, since several other medications (<a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>) were also significantly associated with this complication [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">USE IN PREGNANCY</span><span class="headingEndMark"> — </span>There does not appear to be an increased risk of birth defects when <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> is administered during the first trimester of pregnancy; however, controlled studies documenting safety are lacking. Prospective epidemiologic registries of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> and valacyclovir in pregnancy, which collected data through 1999, found that the rate of birth defects among 784 infants and fetuses exposed to these agents during the first trimester was not significantly different from that of the population not exposed to these agents [<a href="#rid1">1</a>]. Similar findings were demonstrated in a study of 1804 first-trimester pregnancies in Denmark exposed to acyclovir, valacyclovir, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> from 1996 to 2008, in which the frequency of major birth defects in exposed infants was not increased compared with those who were not exposed (2.2 versus 2.4 percent, adjusted prevalence odds ratio 0.89; 95% CI 0.65-1.22) [<a href="#rid8">8</a>]. With regards to the individual antiviral agents, a major birth defect was diagnosed in 32 of 1561 infants (2.0 percent) with first-trimester exposure to acyclovir and 7 of 229 infants (3.1 percent) with first-trimester exposure to valacyclovir; famciclovir exposure was uncommon, with 1 of 26 infants (3.8 percent) diagnosed with a birth defect. </p><p>Although the relatively small size of available data yield insufficient power to draw definitive conclusions regarding the safety of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> and <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> in pregnancy, there are circumstances in which the potential benefits of acyclovir and valacyclovir in pregnancy outweigh the risks, given the high potential morbidity of perinatally acquired herpes simplex virus infection. However, valacyclovir is typically considered an alternative to acyclovir in pregnancy since there is less experience with the use of this agent. (See  <a class="medical medical_review" href="/d/html/8340.html" rel="external">"Genital herpes simplex virus infection and pregnancy"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a> can generally be regarded as an acceptable alternative to oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> when this drug is indicated and features a more convenient dosing schedule. The use of valacyclovir in such conditions is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8282.html" rel="external">"B virus infection"</a> and  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8346.html" rel="external">"Treatment of genital herpes simplex virus infection"</a> and  <a class="medical medical_review" href="/d/html/8287.html" rel="external">"Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults"</a>.) </p><p class="headingAnchor" id="H1564280"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a> is converted in vivo to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, a nucleoside analog that competitively inhibits viral DNA polymerase. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a> is active in vitro against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus (EBV), but is not usually used clinically for EBV infections. Valacyclovir has three to fivefold greater oral bioavailability (about 55 percent) than <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. (See <a class="local">'Basic pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism of resistance to <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> is identical to that described for <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host: reduced or absent thymidine kinase, altered thymidine kinase activity, and altered viral DNA polymerase with decreased affinity for acyclovir triphosphate. (See <a class="local">'Mechanism of resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When administered at approved doses (up to 1000 mg three times daily or two 2000 mg doses separated by 12 hours), <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> is well tolerated. (See <a class="local">'Toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There does not appear to be an increased risk of birth defects when <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> is administered during the first trimester of pregnancy; however, controlled studies documenting safety are lacking. (See <a class="local">'Use in pregnancy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">Valacyclovir</a> can generally be regarded as an acceptable alternative to oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> when this drug is indicated and offers a more convenient dosing schedule. (See <a class="local">'Clinical use'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Valtrex (valacyclovir hydrochloride) prescribing information, Glaxo Wellcome Inc, 2019. https://www.gsksource.com/gskprm/htdocs/documents/VALTREX-PI-PIL.PDF (Accessed on July 21, 2020).</li><li><a class="nounderline abstract_t">Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs 1996; 52:17.</a></li><li><a class="nounderline abstract_t">Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52:754.</a></li><li><a class="nounderline abstract_t">Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47:855.</a></li><li><a class="nounderline abstract_t">Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.</a></li><li><a class="nounderline abstract_t">Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.</a></li><li><a class="nounderline abstract_t">Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.</a></li><li><a class="nounderline abstract_t">Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304:859.</a></li></ol></div><div id="topicVersionRevision">Topic 8337 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.gsksource.com/gskprm/htdocs/documents/VALTREX-PI-PIL.PDF" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Valtrex (valacyclovir hydrochloride) prescribing information, Glaxo Wellcome Inc, 2019. https://www.gsksource.com/gskprm/htdocs/documents/VALTREX-PI-PIL.PDF (Accessed on July 21, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8799682" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New antiherpesvirus agents. Their targets and therapeutic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118821" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389118" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416838" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Resistance of herpesviruses to antiviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419169" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9352739" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736469" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
